信件：2019冠状病毒病的结局与抗TNF治疗——全面的证据很重要。作者回复。
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
作者信息
Kokkotis Georgios, Kitsou Konstantina, Bamias Giorgos
机构信息
GI Unit, 3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Immunobiology and Vaccinology Research Lab, First Department of Paediatrics, "Aghia Sophia" Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Aliment Pharmacol Ther. 2022 May;55(9):1235-1236. doi: 10.1111/apt.16904.
Abstract
This article is linked to Kokkotis et al papers. To view these articles, visit https://doi.org/10.1111/apt.16717 and https://doi.org/10.1111/apt.16872
摘要
本文与科科蒂斯等人的论文相关联。要查看这些文章，请访问https://doi.org/10.1111/apt.16717和https://doi.org/10.1111/apt.16872
相似文献
1
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.信件：2019冠状病毒病的结局与抗TNF治疗——全面的证据很重要。作者回复。
Aliment Pharmacol Ther. 2022 May;55(9):1235-1236. doi: 10.1111/apt.16904.
2
Letter: immunogenicity of anti-TNF in elderly IBD patients-authors' reply.信件：老年炎症性肠病患者中抗 TNF 的免疫原性——作者回复。
Aliment Pharmacol Ther. 2019 Aug;50(3):337. doi: 10.1111/apt.15379.
3
Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply.信函：预测炎症性肠病中抗TNF谷浓度及抗药物抗体与治疗停药情况。作者回复。
Aliment Pharmacol Ther. 2021 Aug;54(4):538-539. doi: 10.1111/apt.16501.
4
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply.信函：在抗TNF难治性克罗恩病中选择优特克单抗和维多珠单抗——细节决定成败。作者回复
Aliment Pharmacol Ther. 2020 Aug;52(3):563-564. doi: 10.1111/apt.15888.
5
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters.信：COVID-19 结局和抗 TNF 治疗——全面的证据很重要。
Aliment Pharmacol Ther. 2022 May;55(9):1233-1234. doi: 10.1111/apt.16872.
6
Reply to "Patients With Inflammatory Bowel Disease on Anti-TNF Therapy and COVID-19 Vaccination".对《接受抗TNF治疗的炎症性肠病患者与COVID-19疫苗接种》的回复
Inflamm Bowel Dis. 2023 Mar 1;29(3):e8-e9. doi: 10.1093/ibd/izad006.
7
Editorial: anti-TNF therapy-a double-edged sword? Authors' reply.社论：抗TNF治疗——一把双刃剑？作者回复。
Aliment Pharmacol Ther. 2019 Oct;50(7):823-824. doi: 10.1111/apt.15459.
8
Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.社论：抗TNF“治疗持续性”是否总是等同于“有效治疗”？只有客观的疾病评估才能回答这个问题。作者回复。
Aliment Pharmacol Ther. 2021 Sep;54(5):720-721. doi: 10.1111/apt.16535.
9
Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.社论：英夫利昔单抗或阿达木单抗作为一线或二线抗TNF药物——相互矛盾的证据——作者回复
Aliment Pharmacol Ther. 2021 Sep;54(6):848-849. doi: 10.1111/apt.16569.
10
Editorial: is there a role for monitoring intermediate anti-TNF drug concentrations in IBD? Authors' reply.社论：监测炎症性肠病中抗 TNF 药物的中间浓度是否有作用？作者回复。
Aliment Pharmacol Ther. 2022 Apr;55(8):1051. doi: 10.1111/apt.16893.
本文引用的文献
1
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters.信：COVID-19 结局和抗 TNF 治疗——全面的证据很重要。
Aliment Pharmacol Ther. 2022 May;55(9):1233-1234. doi: 10.1111/apt.16872.
2
Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments.系统评价与荟萃分析：接受抗 TNF 治疗的患者的 COVID-19 结局。
Aliment Pharmacol Ther. 2022 Jan;55(2):154-167. doi: 10.1111/apt.16717. Epub 2021 Dec 8.
3
Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs.COVID-19 死亡率和住院率的时间趋势：来自美国退伍军人事务部的一项观察性队列研究。
BMJ Open. 2021 Aug 16;11(8):e047369. doi: 10.1136/bmjopen-2020-047369.
4
Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden.炎症性肠病与 COVID-19 重症风险：瑞典全国基于人群的队列研究。
United European Gastroenterol J. 2021 Mar;9(2):177-192. doi: 10.1002/ueg2.12049. Epub 2021 Mar 11.
5
An assessment of the extent to which the contents of PROSPERO records meet the systematic review protocol reporting items in PRISMA-P.评估 PROSPERO 记录的内容在多大程度上符合 PRISMA-P 系统评价报告条目。
F1000Res. 2020 Jul 27;9:773. doi: 10.12688/f1000research.25181.2. eCollection 2020.
6
Empirical Comparison of Publication Bias Tests in Meta-Analysis.元分析中发表偏倚检验的实证比较。
J Gen Intern Med. 2018 Aug;33(8):1260-1267. doi: 10.1007/s11606-018-4425-7. Epub 2018 Apr 16.
7
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.随机对照试验荟萃分析中检查和解释漏斗图不对称性的建议。
BMJ. 2011 Jul 22;343:d4002. doi: 10.1136/bmj.d4002.
Zotero 插件